Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

This week, researchers in the US were told to remove all references to mRNA vaccine technology from their grant applications to the National Institutes of Health. It is thought this move could be a ...

Add Yahoo as a preferred source to see more of our stories on Google. HHS Secretary Robert F. Kennedy Jr., speaks at an event where Secretary of Agriculture Brooke Rollins signed SNAP food choice ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one of the worst performers on Wednesday. Moderna surged to a new 52-week high ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

The team applied this method to mRNA/saRNA constructs from 1 to 10 kb and assessed pH ranges from 3 to 6. For all the RNA constructs, the J2 immunoblot signal—a marker for dsRNA strands—decreased with ...